FDA Background for Colon Cancer Endpoints Workshop

First Page		Document Content
Prodrugs Organofluorides Oxaliplatin Chemotherapy regimens Capecitabine Irinotecan Adjuvant therapy FOLFOX Levamisole Chemistry Medicine Pharmacology		FDA Background for Colon Cancer Endpoints Workshop Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 395,76 KB Share Document on Facebook

	Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion Idursulfase ▼This medicine is subject to additional monitoring. This will allow quick identification of new safety inform DocID: 1reFq - View Document
	Bevacizumab+ FOLFOX (f.d.OxModdG) (colorektal) Bevacizumab (Avastin) 5 mg/kg (om lämpligt, jämna 100-tal) iv infmin iv infmin DocID: 1e3Ep - View Document
	Cetuximab/FOLFOX Cetuximab Oxaliplatin Calciumfolinat 5-Fluorouracil 5-Fluorouracil DocID: 1d2uk - View Document
	7.5 PANITUMUMAB, injection, 100 mg/5 mL and 400 mg/20 mL, Vectibix®, Amgen Australia Pty Ltd. Purpose of Application To request that the current Section 100 (Efficient Funding of Chemotherapy Program) Authority Require DocID: 17GB7 - View Document
	PAR Oxaliplatin 5 mg / ml Concentrate for Solution for Infusion PL; UK/HDC Public Assessment Report Decentralised Procedure DocID: 16sDl - View Document